
News|Videos|November 1, 2023
Optimizing Combination Therapy in Advanced Prostate Cancer
Author(s)David Morris, MD, FACS , Benjamin Garmezy, MD
Explore the criteria for considering doublet or triplet therapies in advanced prostate cancer, examining their potential benefits and minimal added toxicity as discussed by key opinion leaders.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5



















